Abiopharma

OncoCyte Corporation (OCX) Announces Executive and Board Changes OncoCyte Corporation (OCX) announced changes to its leadership team and board of directors. The change is effective as of June 24, 2022. Executive Changes Details:

• Actions: Departed
  • anticipated in these forward-looking statements are contained in Oncocyte Corporation’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) under the heading “Risk Factors” and in other filings that Oncocyte may make with the SEC. Undue reliance should not be placed on these forward-looking statements which speak only as of the date they are made, and the facts and assumptions underlying these statements may change. Except as required by law, Oncocyte disclaims any intent or obligation to update these forward-looking statements. References to “Oncocyte,” the “Company,” we,” “us,” and “our” are references to Oncocyte Corporation. Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective June 24, 2022